Name the product before judging it
In your treatment notes, the word “peptide” describes a short chain of joined chemical parts. Those small parts also make the longer chains known as proteins. Insulin is one member of the peptide group. This describes makeup alone; effects and permission to use a product as medicine are separate questions.
Ask which exact product is proposed, what form it comes in and why it is being proposed. Keep that name when you ask for evidence.
Keep approval tied to the named use
FDA means the Food and Drug Administration. Its approval concerns a specific medicine and its named uses.
As of September 26, 2026, US law gives no single approval to treatments called “peptide therapy”. Each medicine needs its own check: is it approved, legally made to order or an unapproved product?
Ask which use is approved for the proposed product. Then ask how that relates to the goal you brought to the visit.
Understand a made-to-order medicine
For the medicine line in your notes, “compounding” means preparing medicine for an order rather than using an approved product supplied ready-made.
FDA states, as of September 26, 2026, that compounded drugs lack FDA approval and pre-sale review for quality, benefit or safety.
FDA says compounding may help address a medical need that remains beyond what an approved product can provide.
Ask why the proposed preparation is needed in your case, rather than treating “made to order” as proof of a better result.
Ask about permission to compound
Under rules checked September 26, 2026, an ordinary pharmacy cannot routinely make copies of a medicine already sold ready-made, or make those copies in large amounts.
The prescriber is the person licensed to write a prescription for medicine.
There is an exception for a changed medicine made for a named patient. The prescriber must judge that the change provides a significant medical difference for the named patient. A price reduction by itself does not satisfy this condition.
Ask what would change from the ready-made medicine and why that change matters for you. Having a prescription alone leaves that question unanswered.
For retatrutide and cagrilintide, FDA states that federal law does not allow their use in compounding, as of September 26, 2026.
These are product names you may encounter on a treatment page. Ask for the source of any claim that a product can be supplied.
Read the result beside your goal
Ask who was studied, what was measured and how long the study followed people. Ask what the result can tell you about your own aim.
If a page promises a result but gives no source to read, keep that question open.
Read beside this note
- FDA’s compounding explanation
This explains product status and medical need. It does not establish that a preparation improves the outcome you want.
- FDA on weight-medicine product concerns
Read this for FDA’s stated position on retatrutide and cagrilintide.